Results from an observational trial: Digital epiluminescence Microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma

被引:104
作者
Haenssle, Holger A.
Krueger, Ullrich
Vente, Claudia
Thoms, Kai-Martin
Bertsch, Hans P.
Zutt, Markus
Rosenberger, Albert
Neumann, Christine
Emmert, Steffen
机构
[1] Univ Gottingen, Dept Dermatol, D-37073 Gottingen, Germany
[2] Univ Gottingen, Dept Genet Epidemiol, D-37073 Gottingen, Germany
关键词
D O I
10.1038/sj.jid.5700119
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
We analyzed the value of digital epiluminescence microscopy (DELM) for the long-term follow-up of atypical nevi. Patients (n = 530) were prospectively categorized into defined melanoma risk groups and followed by clinical and epiluminescence microscopy (ELM) examinations. Atypical nevi (n = 7001) were additionally followed by DELM. During follow-up (median 32.2 months), we detected 53 melanomas among 637 excised lesions (8.3% overall chance of success). The chance of success for melanoma detection among lesions suspicious by ELM criteria was increased to 17% when additional DELM-documented changes were present. Moreover, 18 of the 53 melanomas were exclusively identified by DELM-documented changes, indicating that DELM increased the sensitivity of the ELM analysis by identifying additional melanomas. However, for lesions exclusively excised due to DELM changes, the chance of success was lower than for ELM (5.2 vs 11.8%). Excisions due to mere DELM changes detected 66.7% of melanomas in familial atypical mole and multiple melanoma (FAMMM) and 32.5% of melanomas in atypical mole syndrome (AMS) patients. We conclude that DELM is a valuable tool for the long- term follow- up of atypical nevi, especially in the high- risk groups of FAMMM and AMS patients. Randomized controlled trials are needed to validate the data from this clinical trial.
引用
收藏
页码:980 / 985
页数:6
相关论文
共 20 条
[1]   The impact of dermoscopy on the management of pigmented skin lesions: The role of follow-up [J].
Argenziano, G .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (01) :178-178
[2]   Sensitivity and specificity of epiluminescence microscopy:: evaluation on a sample of 2731 excised cutaneous pigmented lesions [J].
Ascierto, PA ;
Palmieri, G ;
Celentano, E ;
Parasole, R ;
Caracò, C ;
Daponte, A ;
Chiofalo, MG ;
Melucci, MT ;
Mozzillo, N ;
Satriano, RA ;
Castello, G .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 142 (05) :893-898
[3]   Epiluminescence microscopy-based classification of pigmented skin lesions using computerized image analysis and an artificial neural network [J].
Binder, M ;
Kittler, H ;
Seeber, A ;
Steiner, A ;
Pehamberger, H ;
Wolff, K .
MELANOMA RESEARCH, 1998, 8 (03) :261-266
[4]   Two types of pattern modification detected on the follow-up of benign melanocytic skin lesions by digitized epiluminescence microscopy [J].
Braun, RP ;
Lemonnier, E ;
Guillod, J ;
Skaria, A ;
Salomon, D ;
Saurat, JH .
MELANOMA RESEARCH, 1998, 8 (05) :431-437
[5]  
Breslow A, 1980, Pathol Annu, V15, P1
[6]   Improvement of malignant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study 1997-2001 [J].
Carli, P ;
De Giorgi, V ;
Crocetti, E ;
Mannone, F ;
Massi, D ;
Chiarugi, A ;
Giannotti, B .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (04) :687-692
[7]   Addition of dermoscopy to conventional naked-eye examination in melanoma screening: A randomized study [J].
Carli, P ;
de Giorgi, V ;
Chiarugi, A ;
Nardini, P ;
Weinstock, MA ;
Crocetti, E ;
Stante, M ;
Giannotti, B .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (05) :683-689
[8]   Why digital follow-up of dermoscopically equivocal pigmented lesions should be discouraged [J].
Carli, P ;
De Giorgi, V ;
Giannotti, B .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (06) :1272-1273
[9]   Clinically and dermoscopically featureless melanoma: When prevention fails [J].
Carli, P ;
Massi, D ;
de Giorgi, V ;
Giannotti, B .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (06) :957-959
[10]  
Greene MH, 1999, CANCER-AM CANCER SOC, V86, P2464, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2464::AID-CNCR3>3.0.CO